Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Pharma-Bio Serv (PBSV) Invested Capital (2016 - 2026)

Pharma-Bio Serv's Invested Capital history spans 16 years, with the latest figure at $10.2 million for Q1 2026.

  • For Q1 2026, Invested Capital fell 14.65% year-over-year to $10.2 million; the TTM value through Jan 2026 reached $10.2 million, down 14.65%, while the annual FY2025 figure was $11.9 million, 13.13% down from the prior year.
  • Invested Capital reached $10.2 million in Q1 2026 per PBSV's latest filing, down from $11.9 million in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $17.4 million in Q1 2022 to a low of $10.2 million in Q1 2026.
  • Average Invested Capital over 5 years is $14.4 million, with a median of $14.2 million recorded in 2024.
  • Peak YoY movement for Invested Capital: crashed 32.26% in 2022, then grew 0.23% in 2023.
  • A 5-year view of Invested Capital shows it stood at $16.6 million in 2022, then fell by 2.6% to $16.1 million in 2023, then fell by 14.95% to $13.7 million in 2024, then decreased by 13.13% to $11.9 million in 2025, then fell by 14.06% to $10.2 million in 2026.
  • Per Business Quant, the three most recent readings for PBSV's Invested Capital are $10.2 million (Q1 2026), $11.9 million (Q4 2025), and $11.9 million (Q3 2025).